Identifying sources and estimating glandular output of salivary TIMP‐1

References

• Kaufman E., Lamster I. B. The diagnostic applications of saliva – a review. Crit Rev Oral Biol Med 2002; 13: 197–212
   PubMedGoogle Scholar
• Lawrence H. P. Salivary markers of systemic disease: noninvasive diagnosis of disease and monitoring of general health. J Can Dent Assoc 2002; 68: 170–4
   PubMedGoogle Scholar
• Holten‐Andersen M. N., Stephens R. W., Nielsen H. J., Murphy G., Christensen I. J., Stetler‐Stevenson W., et al. High preoperative plasma tissue inhibitor of metalloproteinase‐1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000; 6: 4292–9
   PubMed Web of Science ®Google Scholar
• Holten‐Andersen M. N., Christensen I. J., Nielsen H. J., Stephens R. W., Jensen V., Nielsen O. H., et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002; 8: 156–64
   PubMed Web of Science ®Google Scholar
• Schrohl A. S., Christensen I. J., Pedersen A. N., Jensen V., Mouridsen H., Murphy G., et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases‐1 (TIMP‐1) and plasminogen activator inhibitor type 1 (PAI‐1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2003; 2: 164–72
   PubMed Web of Science ®Google Scholar
• Schrohl A. S., Holten‐Andersen M. N., Peters H. A., Look M. P., Meijer‐van Gelder M. E., Klijn J. G., et al. Tumor tissue levels of tissue inhibitor of metalloproteinase‐1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004; 10: 2289–98
   PubMed Web of Science ®Google Scholar
• Ylisirnio S., Hoyhtya M., Turpeenniemi‐Hujanen T. Serum matrix metalloproteinases ‐2, ‐9 and tissue inhibitors of metalloproteinases ‐1, ‐2 in lung cancer–TIMP‐1 as a prognostic marker. Anticancer Res 2000; 20: 1311–16
   PubMed Web of Science ®Google Scholar
• Suemitsu R., Yoshino I., Tomiyasu M., Fukuyama S., Okamoto T., Maehara Y. Serum tissue inhibitors of metalloproteinase‐1 and ‐2 in patients with non‐small cell lung cancer. Surg Today 2004; 34: 896–901
   PubMed Web of Science ®Google Scholar
• Gouyer V., Conti M., Devos P., Zerimech F., Copin M. C., Creme E., et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer 2005; 103: 1676–84
   PubMed Web of Science ®Google Scholar
• Manenti L., Paganoni P., Floriani I., Landoni F., Torri V., Buda A., et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003; 39: 1948–56
   PubMed Web of Science ®Google Scholar
• Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., Okumura K. Plasma levels of matrix metalloproteinase‐9 and tissue inhibitor of metalloproteinase‐1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141: 211–17
   PubMed Web of Science ®Google Scholar
• Tayebjee M. H., Nadar S., Blann A. D., Gareth Beevers D., MacFadyen R. J., Lip G. Y. Matrix metalloproteinase‐9 and tissue inhibitor of metalloproteinase‐1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo‐Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17: 764–9
   PubMed Web of Science ®Google Scholar
• Nanni S., Melandri G., Hanemaaijer R., Cervi V., Tomasi L., Altimari A., et al. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res 2007; 149: 137–44
   PubMedGoogle Scholar
• Jguirim‐Souissi I., Jelassi A., Addad F., Hassine M., Najah M., Ben Hamda K., et al. Plasma metalloproteinase‐12 and tissue inhibitor of metalloproteinase‐1 levels and presence, severity, and outcome of coronary artery disease. Am J Cardiol 2007; 100: 23–7
   PubMedGoogle Scholar
• Ishimura E., Nishizawa Y., Shoji S., Mori H. Serum type III, IV collagens and TIMP in patients with type II diabetes mellitus. Life Sci 1996; 58: 1331–7
   PubMedGoogle Scholar
• Maxwell P. R., Timms P. M., Chandran S., Gordon D. Peripheral blood level alterations of TIMP‐1, MMP‐2 and MMP‐9 in patients with type 1 diabetes. Diabet Med 2001; 18: 777–80
   PubMed Web of Science ®Google Scholar
• Lee S. W., Song K. E., Shin D. S., Ahn S. M., Ha E. S., Kim D. J., et al. Alterations in peripheral blood levels of TIMP‐1, MMP‐2, and MMP‐9 in patients with type‐2 diabetes. Diabetes Res Clin Pract 2005; 69: 175–9
   PubMed Web of Science ®Google Scholar
• Derosa G., D'Angelo A., Tinelli C., Devangelio E., Consoli A., Miccoli R., et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007; 33: 129–34
   PubMed Web of Science ®Google Scholar
• Ingman T., Tervahartiala T., Ding Y., Tschesche H., Haerian A., Kinane D. F., et al. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin Periodontol 1996; 23: 1127–32
   PubMed Web of Science ®Google Scholar
• Pozo P., Valenzuela M. A., Melej C., Zaldivar M., Puente J., Martinez B., et al. Longitudinal analysis of metalloproteinases, tissue inhibitors of metalloproteinases and clinical parameters in gingival crevicular fluid from periodontitis‐affected patients. J Periodontal Res 2005; 40: 199–207
   PubMed Web of Science ®Google Scholar
• Gorska R., Nedzi‐Gora M. The effects of the initial treatment phase and of adjunctive low‐dose doxycycline therapy on clinical parameters and MMP‐8, MMP‐9, and TIMP‐1 levels in the saliva and peripheral blood of patients with chronic periodontitis. Arch Immunol Ther Exp (Warsz) 2006; 54: 419–26
   PubMedGoogle Scholar
• Navazesh M., Christensen C. M. A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 1982; 61: 1158–62
   PubMed Web of Science ®Google Scholar
• Lashley K. S. Reflex secretion of the human parotid gland. J Exp Psychol 1916; 1: 461–93
   Google Scholar
• Truelove E. L., Bixler D., Merritt A. D. Simplified method for collection of pure submandibular saliva in large volumes. J Dent Res 1967; 46: 1400–3
   PubMed Web of Science ®Google Scholar
• Moller Sorensen N., Dowell B. L., Stewart K. D., Jensen V., Larsen L., Lademann U., et al. Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases‐1. Tumour Biol 2005; 26: 71–80
   PubMedGoogle Scholar
• Holten‐Andersen M. N., Murphy G., Nielsen H. J., Pedersen A. N., Christensen I. J., Hoyer‐Hansen G., et al. Quantitation of TIMP‐1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999; 80: 495–503
   PubMed Web of Science ®Google Scholar
• Hembry R. M., Murphy G., Reynolds J. J. Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of a specific antiserum. J Cell Sci 1985; 73: 105–19
   PubMed Web of Science ®Google Scholar
• Murphy G., Houbrechts A., Cockett M. I., Williamson R. A., O'Shea M., Docherty A. J. The N‐terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991; 30: 8097–102
   PubMed Web of Science ®Google Scholar
• Cooksley S., Hipkiss J. B., Tickle S. P., Holmes‐Ievers E., Docherty A. J., Murphy G., et al. Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme‐inhibitor complexes. Matrix 1990; 10: 285–91
   PubMedGoogle Scholar
• Lindmark G., Bergstrom R., Pahlman L., Glimelius B. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer 1995; 71: 1090–4
   PubMedGoogle Scholar
• Thaysen‐Andersen M., Thogersen I. B., Nielsen H. J., Lademann U., Brunner N., Enghild J. J., et al. Rapid and individual‐specific glycoprofiling of a low‐abundant N‐glycosylated protein tissue inhibitor of metalloproteinases‐1. Mol Cell Proteomics 2007
   PubMedGoogle Scholar
• Holten‐Andersen M. N., Brunner N., Nielsen H. J., Christensen I. J., Sorensen N. M., Rasmussen A. S., et al. Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer. Int J Biol Markers 2006; 21: 6–11
   PubMedGoogle Scholar
• Ferguson D. B., Botchway C. A. A comparison of circadian variation in the flow rate and composition of stimulated human parotid, submandibular and whole salivas from the same individuals. Arch Oral Biol 1980; 25: 559–68
   PubMedGoogle Scholar
• Dawes C., Ong B. Y. Circadian rhythms in the flow rate and proportional contribution of parotid to whole saliva volume in man. Arch Oral Biol 1973; 18: 1145–53
   PubMed Web of Science ®Google Scholar
• Humphrey S. P., Williamson R. T. A review of saliva: normal composition, flow, and function. J Prosthet Dent 2001; 85: 162–9
   PubMed Web of Science ®Google Scholar
• Lamster I. B., Ahlo J. K. Analysis of gingival crevicular fluid as applied to the diagnosis of oral and systemic diseases. Ann NY Acad Sci 2007; 1098: 216–29
   PubMed Web of Science ®Google Scholar
• Shirtcliff E. A., Granger D. A., Schwartz E., Curran M. J. Use of salivary biomarkers in biobehavioral research: cotton‐based sample collection methods can interfere with salivary immunoassay results. Psychoneuroendocrinology 2001; 26: 165–73
   PubMed Web of Science ®Google Scholar